Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies
ConclusionsIn summary, GCV can cause a diverse range of cancers. Its mutagenicity may be potentiated by other therapies, such as mycophenolate, commonly co-prescribed with GCV for post-transplant patients. Further investigation of the optimal use of these drugs could help reduce GCV-associated mutagenesis in post-transplant patients.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Acyclovir | Cancer | Cancer & Oncology | Cytomegalovirus | Genetics | Statistics | Stem Cell Therapy | Stem Cells | Study | Transplants | Zovirax